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Available online 26 November 2015The Genea016 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated human feeders. The line showed pluripotent cell morphology
and genomic analysis veriﬁed a 46, XX karyotype and female Allele pattern through traditional karyotyping, CGH
and STR analysis. Pluripotency of Genea016was demonstratedwith 77% of cells expressingNanog, 95% Oct4, 53%
Tra1-60 and 98% SSEA4, a PluriTest Pluripotency score of 28.4, Novelty score of 1.37 and Alkaline Phosphatase ac-
tivity. The cell line was negative for Mycoplasma and any visible contamination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Se
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Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was re-
moved with pronase. The embryo was bisected and plated onto mito-
mycin C inactivated Detroit 551 HFF (plated 200,000 cells per organ
culture dish — 69,204 cells/cm2) in 20% Knock out serum in standard
hESC culture medium (Amit et al. 2000) with 50 ng/ml Fgf2.
Karyotyping, CGH and DNA proﬁling was performed at the ﬁrst
cryobanking step from ICMoutgrowthsmaintained on feeders. Alkaline
Phosphatase staining was performed on feeders. Cells were then
enzymatically passaged as single cells and genetic analysis repeated as
well as immunoﬂuorescent pluripotent marker staining, PluriTest and
sterility testing performed.
Genetic analysis
1. Karyotyping: Passage 5; for the enrichment ofmetaphase cells, cellu-
lar outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysisivecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Alkaline Phosphatase staining.
Table 1
CGH analysis summary.
Parameter Result
Sample name Genea016p15_2
Date reported 20th August 2013
Hybridisation balance A balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes N400 kb were detected
Interpretation Female cell line — no abnormalities detected
25B. Dumevska et al. / Stem Cell Research 16 (2016) 24–28by G-banding. A minimum of 15 metaphase cells were examined,
of which full karyotype or chromosome counts were performed
for 5 and 10 of the metaphases respectively.
2. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 15 (13 on feeders, 2 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and du-
plications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner C
and analysed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).
3. DNA Proﬁling: Passage 5; DNA ‘ﬁngerprinting’ was performed
using the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (AppliedFig. 2. KaryBiosystems #4322288) to provide permanent genetic identiﬁca-
tion of the cell lines. https://www.thermoﬁsher.com/order/
catalog/product/4322288
Pluripotency assessment
1. Alkaline Phosphatase: Passage 21; Genea016 was stained as per
manufacturers protocol using theMerckMillipore Alkaline Phospha-
tase Detection Kit (SCR004).
2. Immunoﬂuorescence: Passage 15 (13 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
3. PluriTest: Passage 15 (13 on feeders, 2 enzymatic); RNA was collect-
ed and subjected to a PluriTest, a bioinformatic assay of pluripotency
in human cells based on gene expression proﬁles (Müller et al. 2012).
Sterility testing
1. Mycoplasma: Passage 27; testing was performed at the Victorian In-
fectious Diseases Reference Laboratory using Mycoplasma Genus
PCR.otype.
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our QC measures. Cells were thawed and cultured in 7 ml antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. AFig. 3. DNA proﬁlinclear solution at ~48–72 h indicated a lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.g certiﬁcation.
Fig. 4. Percentage of cells expressing SSEA4, Nanog, Oct3/4 and Tra1/60 as detected by immunoﬂuorescence. A: Immunoﬂuorescence staining. B: Immunoﬂuorescence quantiﬁcation.
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Fig. 5. PluriTest.
28 B. Dumevska et al. / Stem Cell Research 16 (2016) 24–28Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Development of human embryonic
stem cells from excess ART embryos’) was obtained from the Genea
Ethics Committee on 21 February 2001. Excess ART embryos were
fully consented for stem cell derivation by all responsible people
through an informed consent process (signed de-identiﬁed consent
form can be provided upon request). Donors have received no payment
or ﬁnancial beneﬁts for their donation. Genea016has been derived from
a donated, fully commercially consented human embryo, originallycreated by assisted reproduction technology (ART) for the purpose of
procreation, under Australian National Health and Medical Research
Council (NHMRC) licence 309703. This licence was issued to GENEA
on 16 April 2004. More information about the licence can be obtained
from the NHMRC webpage at http://www.nhmrc.gov.au/health-
ethics/human-embryos-and-cloning/database-licences-authorising-
use-excess-art-embryos.
Morphology
The derived stem cell line, Genea016, morphologically displays an
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1).
Genetic analysis
The cell line has been karyotyped, demonstrating a 46, XX karyotype
(Fig. 2, Supplementary Figure 1), consistent with CGH (Table 1, Supple-
mentary Figure 2) and original derivation. Analysis of STR markers
showed Allele pattern consistent with female genotype (Fig. 3, Supple-
mentary Figure 3).
Disease status
Unaffected.
Pluripotency
GENEA016 is pluripotent by:
1. Alkaline Phosphatase stain positivity (Fig. 1);
2. immunoﬂuorescence with 77% Nanog positive, 95% Oct4, 53% Tra1-
60 and 98% SSEA4 (Fig. 4A, quantiﬁed in 4B); and
3. PluriTest with a 28.4 Pluripotency score and 1.37 Novelty score
(Fig. 5).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Figure 4).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.11.009.
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